Experiences with

Diethylstilbestrol

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer - Annals of Oncology https://www.annalsofoncology.org/article/S0923-7534(19)40829-6/fulltext

Prior to that time most men who experienced Biochemical Recurrence (BCR) of prostate cancer after primary treatments were given an inexpensive, synthetic, and very effective estrogen pill called Diethylstilbestrol (DES).

The latter was done with diethylstilbestrol (DES) offered as fosfestrol and many further names. In India diethylstilbestrol is offered as Honvan and still used today against prostate cancer. In men, the required estrogen is produced from testosterone.

To the best of my knowledge DES (diethylstilbestrol), which was an 'oral' estrogen is no longer available due to the increased risk of cardio events. That's my story and I'm sticking to it! Feel free to contact me...Ron

The study by Byar was also able to show a contributing effect of insufficient androgen suppression on overall mortality, however, this effect was observed with the administration of diethylstilbestrol (23), and unlike our current study, not with LHRH analogues in conjunction with abiraterone acetate

Note: "Patients who progressed were offered diethylstilbestrol." [DES] "[u]Fifty percent of patients subsequently responded to low-dose diethylstilbestrol.[/u]" DES, of course, is the synthetic estrogen that was standard for 30-40 years before Lupron.

I imagine most of you know something about the old, synthetic, oral estrogen DES (diethylstilbestrol) that was used as ADT until the mid 80's when it was discontinued and replaced with Lupron (leuprolide).

Chemicals that are known endocrine disruptors include diethylstilbestrol (the synthetic estrogen DES), dioxin and dioxin-like compounds, polychlorinated biphenyls (PCBs), DDT, and some other pesticides.

KEYWORDS: castrate resistant prostate cancer; diethylstilbestrol PMID: 31249748 PMCID: PMC6579324 DOI: 10.7759/cureus.4470

-Patrick [1] https://en.wikipedia.org/wiki/Diethylstilbestrol

acetate •CP = capsular penetration •CRPC = castration-resistant prostate cancer •CREAT = creatinine •CRYO = cryotherapy, cryoablation, cryosurgery •CS = clinical stage •CT SCAN = computerized tomography (also known as CAT scan or CT scan) •D = diploid •DART = dynamic adaptive radiation therapy •DES = diethylstilbestrol

We are 30+ years into the Lupron era, but diethylstilbestrol [DES] was used for about 45 years before that & shouldn't be entirely ignored. DES is a synthetic estrogen.

The study by Byar was also able to show a contributing effect of insufficient androgen suppression on overall mortality, however, this effect was observed with the administration of diethylstilbestrol (23), and unlike our current study, not with LHRH analogues in conjunction with abiraterone acetate

It is fairly well-known that the old ADT treatment, diethylstilbestrol [DES], a synthetic estradiol, increased the risk for thromboembolic events, but it appears that castration therapy can also increase risk. Nattokinase can accelerate the breakdown of the fibrin in growing clots.

Remarkably, 3 mg per day of diethylstilbestrol (DES) taken orally maintained disease stability for 24 years, at which time his PSA began to rise despite a castrate level of testosterone (28 ng/dl). His bone scan showed metastatic disease to the thoracic spine, sternum, and multiple ribs.

DES (diethylstilbestrol), a synthetic form of estrogen, was used between the early 1940s and 1971.Women who took DES during pregnancy to prevent certain complications are at a slightly higher risk for breast cancer.This does not appear to be the case for their daughters who were exposed to DES before

In a paper published last month [1]: "{Endocrine disruptors}, including diethylstilbestrol (DES), bisphenol A (BPA), and genistein (a phytoestrogen derived from soybeans), have been implicated in the malformation of reproductive organs and later development of disease."

OK, but before Lupon (1985), the synthetic estrogen Diethylstilbestrol [DES] had been used since 1941. High doses (5 mg or higher) were associated with thromboembolic events. Today, there is interest in DES at 1 mg or thereabouts, which is considered to be less risky.

Diethylstilbestrol (DES) is a synthetic estrogen that was developed to supplement a woman's natural estrogen production.